RSS Feed
Search Ask-Cato.com
Tags
adverse events biologics biosimilar biotech cancer Cato BioVentures Cato Research CDER clinical investigator clinical research clinical trials CMC conference CROs DIA drug development eCTD efficacy FDA funding GlobalSubmit guidance Health Canada IND in vitro diagnostics labeling manufacturing marketing application medical devices NDA NIH nonclinical research oncology Phase 1 Phase 2 postmarketing protocol regulatory affairs safety statistical analysis toxicology transparency venture capital warning letters webinarCategories
- Clinical Trials (52)
- Conferences and Meetings (34)
- eCTD (26)
- FDA (71)
- Guest Posts (5)
- Health Canada (6)
- Industry News (56)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (36)
- Social Media (6)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (10)
- Webinars (24)
Tag Archives: Cancer Advances
Early Oncology Partnering Forum
From 21-22 February 2011, Cato Research will be attending the Early Oncology Partnering Forum held in San Francisco, CA. This conference facilitates and encourages discussion and collaborations between companies that are developing innovative products with more established companies as partners. … Continue reading
Posted in Conferences and Meetings
Tagged biotech, Cancer Advances, Cato Research, clinical trials, Colorectal cancer, conference, early, gastric cancer, immune system, pancreatic cancer, San Francisco
Comments Off
35th European Society for Medical Oncology Congress
Image via Wikipedia The annual European Society for Medical Oncology (ESMO) meeting brings together medical oncologists from both Europe and all parts of the world. As per ESMO’s 2010 meeting President, Dr. David Kerr, announcement: The ESMO Congress is a … Continue reading
Approval of Therapeutic Cancer Vaccines
Last month, Dendreon was granted approval for Provenge®, the first cell based cancer vaccine for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Provenge is the first cancer treatment that utilizes the strength of the … Continue reading
Posted in FDA, Industry News, Publications
Tagged biomedical, cancer, Cancer Advances, cancer vaccine, Cato BioVentures, clinical benefit, clinical development, Dendreon, drug development, gastric cancer, gastrointestinal cancers, immune system, immunomodulators, Journal for Clinical Studies, monoclonal antibody therapy, pancreatic cancer, Provenge, serum-derived polyclonal treatment, targeted therapeutics, tumors
1 Comment
